The BCD-100–5/FERMATA clinical study will evaluate the main efficacy parameters of BCD-100 in patients with advanced cervical cancer who:
Are diagnosed with "histologically confirmed cervical cancer" (of the following histological types: squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma).
Have progressive disease or recurrence after radical treatment, or have FIGO stage IVB primary metastatic cervical cancer.
Are aged 18 years or older.
Participation of a maximum of 318 people in the Russian Federation has been approved for this study.
The BCD-100-5/FERMATA study takes place at 51 study centers in Moscow, Saint Petersburg, and other cities in the Russian Federation.
This study is also conducted in the PRC.
You can ask questions about participation in the clinical study and request contact information about study centers using a special form «Do you have any questions?».
Authorization of the Ministry of Health of the Russian Federation for this clinical study, No. 312 dated June 17, 2019, and the list of approved study centers have been published in the State Register of Medicines.